Rutin
Phase 2Small molecule
Rutin is one of 77 small molecule programs targeting Bladder Cancer. It is currently in Phase 2.
2
Indications
3
Total Trials
1
Active Trials
76
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Orencia
Bristol-Myers SquibbPhase 3
Icotyde
Johnson & JohnsonPhase 3
Pulmicort
SSalix
Phase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Purinethol
SStason
Phase 3
Adtralza
LEO PharmaPhase 3
CP-690,550
PfizerPhase 3
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Diosmin
TTanta University
Phase 3
ABX464
AAbivax S.A.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ulcerative Colitis2 trials
Effect of Rutin on Inflammation Pathways in Ulcerative Colitis Patients
Completed·—·Phase 2·NCT07370220·60 enrolled
Rutin Therapy Role in Reducing Ulcerative Colitis Severity
Completed·—·N/A·NCT07147842·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rutin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details